Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05034952 · ClinicalTrials.gov registry record · Phase 2

A Study Evaluating Efficacy and Safety of VX-548 for Acute Pain After an Abdominoplasty

A Phase 2 study of Acute Pain, sponsored by Vertex Pharmaceuticals Incorporated.

Completed
Registry status
Phase 2
Development phase
303
Enrollment target
7
Study locations

NCT05034952 is a Phase 2 study of Acute Pain that has completed, run by Vertex Pharmaceuticals Incorporated. The registered enrollment target is 303 participants, above the 262-participant average among 50 other Acute Pain trials with a reported enrollment target (16% higher). The trial reports 7 study locations across 6 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05034952, a Phase 2 study of Acute Pain, has completed, sponsored by Vertex Pharmaceuticals Incorporated.

COMPLETED
Registry status
Phase 2
Development phase
303 participants
Enrollment target
7
Study locations

Study Summary

The purpose of this study is to evaluate the efficacy and safety of VX-548 doses in treating acute pain after an abdominoplasty.

Conditions Studied

Interventions

  • DRUG VX-548
  • DRUG HB/APAP
  • DRUG Placebo (matched to VX-548)
  • DRUG Placebo (matched to HB/APAP)

Study Locations (7)

Texas

  • First Surgical Hospital - Bellaire
  • Endeavor Clinical Trials - San Antonio

Arizona

  • Arizona Research Center - Phoenix

California

  • Lotus Clinical Research - Pasadena

Maryland

  • Chesapeake Research Group - Pasadena

Ohio

  • Midwest Clinical Research Center - Dayton

Utah

  • JBR Clinical Research - Salt Lake City

Trial Details

FieldValue
Enrollment Target 303 participants
Start Date 2021-08-30
Est. Completion 2021-12-21
Phase Phase 2

Sponsor

Vertex Pharmaceuticals Incorporated

191 total trials

What the Registry Record Tells You About NCT05034952

The ClinicalTrials.gov registry entry for NCT05034952 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 303 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 262-participant average among 50 other Acute Pain trials with a reported enrollment target (16% higher). The listed sponsor is Vertex Pharmaceuticals Incorporated, which has 191 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Acute Pain appearing as the primary indexed condition, and to 4 interventions - of which VX-548 is the first listed.

NCT05034952 reports 7 study locations spanning 6 distinct geographic areas - top geographies include Texas, Arizona, California.

Frequently Asked Questions

What is clinical trial NCT05034952 about?

NCT05034952 is a clinical study titled "A Study Evaluating Efficacy and Safety of VX-548 for Acute Pain After an Abdominoplasty". The purpose of this study is to evaluate the efficacy and safety of VX-548 doses in treating acute pain after an abdominoplasty.

What is the current status of trial NCT05034952?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 303 participants. The study started on 2021-08-30. Estimated completion is 2021-12-21.

What conditions does trial NCT05034952 study?

This clinical trial studies the following conditions: Acute Pain.

What interventions are being tested in trial NCT05034952?

The interventions under investigation include: VX-548 (DRUG), HB/APAP (DRUG), Placebo (matched to VX-548) (DRUG), Placebo (matched to HB/APAP) (DRUG).

Who is sponsoring clinical trial NCT05034952?

This trial is sponsored by Vertex Pharmaceuticals Incorporated, which has 191 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05034952 being conducted?

This trial has 7 study locations across Arizona, California, Maryland, Ohio, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Acute Pain

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.